
About Cybin
Cybin is a publicly listed company based in Toronto (Canada) founded in 2002 by Eric So. Psychedelic therapeutics for psychiatric disorders are developed and provided. It operates on a HealthTech model. The company has 50 employees. Cybin has completed 2 acquisitions, including Adelia Therapeutics and Small Pharma. Its website cybin.com draws about 47 thousand monthly visits. Cybin offers products and services including CYB003, CYB004, and CYB005. Its focus areas include Biotechnology and Neuropsychiatry. Its legal entity is Cybin Corp.
Company details
Cybin is engaged in the development of novel neuropsychiatry therapies aimed at transforming mental health treatment. The company is involved in creating proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches. Therapies such as CYB003 for Major Depressive Disorder, CYB004 for Generalized Anxiety Disorder, and CYB005 for CNS disorders are being developed. Partnerships with world-renowned pioneers and a focus on tryptamine-based therapies are maintained to address unmet needs in mental health. The sector of operation includes biotechnology with a specific emphasis on neuropsychiatry solutions.
- Net Profit-$146.79 M (USD)-80.8as on Mar 31, 2026
- EBITDA-$141.3 M (USD)-38.01as on Mar 31, 2026
- Latest Funding Round$50M (USD), Post-IPO
Jun 2025
- InvestorsDeep Track Capital
& 1 more
- Employee Count50
- Investments & AcquisitionsAdelia Therapeutics
& 1 more
Products & Services of Cybin
Cybin offers a comprehensive portfolio of products and services, including CYB003, CYB004, and CYB005.
Therapy developed for Major Depressive Disorder treatment.
Therapy designed for Generalized Anxiety Disorder treatment.
Therapy targeting CNS disorders under active development.
Funding Insights of Cybin
- Total Rounds 7
- Last Round Post-IPO β $50M
- First Round $477,437
(May 2020)
- Investors Count 2
All 7 funding rounds of Cybin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $50M | Post-IPO | β | β | |
| Mar 2024 | $150M | Post-IPO | β | β | |
| Mar 2022 | $317,098 | Post-IPO | β | β | β |
| Feb 2021 | Post-IPO | β | β | β | |
| Oct 2020 | $27.35M | Post-IPO | β | β | β |
| Jun 2020 | $1.54M | Post-IPO | β | β | β |
| May 2020 | $477,437 | Post-IPO | β | β | β |
2 investors in total: 2 institutional.
Investors in Cybin
Cybin has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Deep Track Capital and High Trail Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
High Trail Capital is engaged in investment management services. | 2019 | hightrailcapital.com |
Investor details for Cybin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cybin
54 people are tracked at Cybin (32 in leadership, 10 in board & advisors, 12 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Eric So | Co-Founder | Leadership |
Aaron Bartlone | COO | Leadership |
Sarah Hamilton | Director Financial Operations & Strategic Operations | Leadership |
Peng Chen | Associate Director | Leadership |
Greg Cavers | CFO | Leadership |
Alex Nivorozhkin | Chief Scientific Officer | Leadership |
Geoff Varty | Head, R&D | Leadership |
Pradip Pathare | Senior Director, Process Chemistry | Leadership |
Lori Challenger | Chief Compliance, Ethics & Administrative Officer | Leadership |
Gabe F. | Chief Legal Officer | Leadership |
Kristen Irizarry | Executive Assistant To Chief Executive Officer | Leadership |
Ryan Richardson | Director, Information Technology | Leadership |
Liz Galic | Director, Operations | Leadership |
Erica Olson | VP, Corporate Controller | Leadership |
Kathy Dorsey | Senior Director Clinical Operations | Leadership |
Meghan Good | Associate Director | Leadership |
Marcelo Gutierrez | Vp, Head Of Clinical Pharmacology | Leadership |
Dnb Amir Inamdar Mbbs Mfpm (Psych) | Chief Medical Officer | Leadership |
Amir Inamdar | Chief Medical Officer | Leadership |
Emma Hodge | Head Of Legal Europe | Leadership |
34 more people are available in the full profile.
Complete people profiles for Cybin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cybin
Cybin is a publicly listed company on the NEO with ticker symbol CYBN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Nov 2020
- Listed onNEO: CYBN
- Listed entityCybin, Inc.
- Exchange sectorHealth technology
- ISINCA4234921076
- Share price11.58 CAD (+4.23% on the day) · 2026-01-05
- Market capitalisation577,773,678.00 CAD
- EPS (diluted, trailing year)-5.43 CAD
- Volume (last session)3,715
- Analyst consensusStrong buy
Financials of Cybin
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -204.6M CAD | -196.9M CAD | |
| 2024 | -113.1M CAD | -142.7M CAD | |
| 2023 | -78.1M CAD | -78.4M CAD | |
| 2022 | -47.5M CAD | -51.3M CAD | |
| 2021 | -67.6M CAD | -63.7M CAD |
Detailed financial statements for Cybin
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cybin
Cybin has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adelia Therapeutics and Small Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Psychedelic-based therapeutics for mental health conditions are developed. | smallpharma.com | London, United Kingdom | 2015 | Aug 2023 | β’β’β’β’ | |
Proprietary psychedelics-based therapeutics for neurodegenerative diseases are developed. | adeliatx.com | Fitchburg, United States | 2020 | Dec 2020 | β’β’β’β’ |
Complete acquisition details for Cybin
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cybin
6 dated milestones of Cybin across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Cybin is founded.
- Funding First funding round of $477K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Adelia Therapeutics.
- Acquisition Acquires Small Pharma.
- Funding Latest funding round, Post-IPO, of $50.0M.
Web traffic of Cybin
The website of Cybin (cybin.com) receives about 47.3K visits a month and ranks #655,046 among all websites worldwide, #6,440 in Investing.
- Monthly visits47.3K
▼ 17.7% vs previous month
- Unique visitors37.8K
per month
- Global rank#655,046
among all websites
- Category rank#6,440
Finance · Investing
- Bounce rate67%
- Pages per visit1.5
- Average visit51 sec
- DevicesDesktop 6% Β· Mobile 94%
Websites whose visitors overlap most with Cybin. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| greenmarketreport.com | 89% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cybin
Complete news archive for Cybin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cybin
Cybin was founded in 2002 and raised its 1st funding round 18 years after it was founded.
Cybin is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Cybin has 50 employees.
Cybin is engaged in the development of novel neuropsychiatry therapies aimed at transforming mental health treatment. The company is involved in creating proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches. Therapies such as CYB003 for Major Depressive Disorder, CYB004 for Generalized Anxiety Disorder, and CYB005 for CNS disorders are being developed. Partnerships with world-renowned pioneers and a focus on tryptamine-based therapies are maintained to address unmet needs in mental health. The sector of operation includes biotechnology with a specific emphasis on neuropsychiatry solutions.
Cybin offers CYB003, CYB004, and CYB005.
Yes, Cybin is publicly traded on NEO under the ticker symbol CYBN.
Cybin has made 2 acquisitions, including Adelia Therapeutics, and Small Pharma.
Cybin has 2 investors. Key investors include Deep Track Capital, and High Trail Capital.
Cybin operates through Cybin Corp..
